The Psychopharmacology Institute provides unbiased, evidence-based online education in clinical psychopharmacology.
Methylphenidate is a CNS stimulant approved for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD). It inhibits the reuptake of dopamine and norepinephrine, increased dopaminergic and noradrenergic activity in the prefrontal cortex may explain its efficacy in ADHD.
This tutorial reviews mechanism of action and relevant features of methylphenidate formulations.
This presentation reviews the essential aspects of this medication including: mechanism of action, indications, pharmacokinetics, adverse effects profile and dosing guidelines.
This video discusses the role of 5-HT1A receptor downregulation in the mechanism of action of SSRIs. The monoamine theory of depression is also reviewed and contrasted with its limitations.
This brief video is an overview on the most common side effect of selective serotonin reuptake inhibitors.
Possible mechanisms for each side effect are also discussed.
This brief article summarizes the clinical uses of valproate in psychiatry. We discuss FDA-approved indications as well as off-label uses. Instead of an exhaustive review, this is a practical overview for clinicians.
Dr. David Veale is consultant Psychiatrist In Cognitive Behaviour Therapy at the South London and Maudsley NHS Trust and The Priory Hospital North London. He is a Visiting Senior Lecturer at the Institute of Psychiatry, King’s College London. He specializes in obsessive compulsive disorder (OCD), body dysmorphic disorder (BDD), health anxiety, depression, and emetophobia.
Dr. Rajnish Mago currently serves as Director of the Mood Disorders Program at the Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. He is Associate Professor of Psychiatry at the Jefferson Medical College.